Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:

NCT ID: NCT00468260 Terminated - Clinical trials for Advanced Malignancies

The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

Start date: May 2007
Phase: Phase 1
Study type: Interventional

To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.

NCT ID: NCT00448396 Completed - Clinical trials for Advanced Malignancies

Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

Start date: March 2007
Phase: Phase 1
Study type: Interventional

To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.

NCT ID: NCT00426140 Completed - Solid Tumors Clinical Trials

Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies

NCT ID: NCT00421044 Completed - Tumors Clinical Trials

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Start date: May 2006
Phase: Phase 1
Study type: Interventional

Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.

NCT ID: NCT00420524 Completed - Tumors Clinical Trials

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Start date: January 2006
Phase: Phase 1
Study type: Interventional

This phase I study will determine the pharmacokinetic profile of patupilone in patients with mild or moderately impaired hepatic function within 2 cycles of treatment. The study population for this trial consists of patients with a documented advanced solid tumor. Patients will be stratified into 3 groups: those with normal liver function, and those with mild or moderate liver dysfunction.

NCT ID: NCT00083525 Completed - Clinical trials for Advanced Malignancies

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

Start date: May 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine in patients with advanced malignancies.